Stockscreener 앱 받기
33.41
6.20%
1.95
시간 외 거래:
34.01
0.60
+1.80%
전일 마감가:
$31.46
열려 있는:
$31.46
하루 거래량:
287.42K
Relative Volume:
0.95
시가총액:
$2.33B
수익:
-
순이익/손실:
$-195.21M
주가수익비율:
-10.52
EPS:
-3.1763
순현금흐름:
$-176.19M
1주 성능:
+6.03%
1개월 성능:
+9.90%
6개월 성능:
+38.69%
1년 성능:
+101.75%
1일 변동 폭
$31.38
$33.50
1주일 범위
$30.49
$33.50
52주 변동 폭
$16.00
$33.50
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
33.41 | 2.20B | 0 | -195.21M | -176.19M | -3.1763 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-09 | 개시 | Wolfe Research | Outperform |
| 2026-03-09 | 개시 | RBC Capital Mkts | Outperform |
| 2025-10-15 | 개시 | H.C. Wainwright | Buy |
| 2025-10-09 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-06-11 | 개시 | Guggenheim | Buy |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-09-25 | 개시 | Wedbush | Outperform |
| 2023-08-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | 개시 | Bryan Garnier | Buy |
| 2022-09-13 | 재개 | JMP Securities | Mkt Outperform |
| 2022-08-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-05-25 | 개시 | JMP Securities | Mkt Outperform |
| 2021-03-02 | 개시 | BofA Securities | Neutral |
| 2021-03-02 | 개시 | Morgan Stanley | Overweight |
| 2021-03-02 | 개시 | Oppenheimer | Outperform |
| 2021-03-02 | 개시 | SVB Leerink | Outperform |
모두보기
Pharvaris Nv 주식(PHVS)의 최신 뉴스
PHVS Technical Analysis & Stock Price Forecast - Intellectia AI
Pharvaris (PHVS) CMO reports 109 shares withheld for RSU tax obligations - Stock Titan
Single capsule rapidly eased most HAE attacks in Pharvaris study - Stock Titan
Pharvaris N.V. (PHVS) Presents at World Orphan Drug Congress (WODC) USA 2026Slideshow - Seeking Alpha
Pharvaris (PHVS) Shows Modest Gains After Recent Pullback, Testing Key ResistanceSystematic Flow - newsline.com
Does Pharvaris (PHVS) have the potential to rally 59.93% as Wall Street analysts expect? - MSN
Pharvaris Sets June 26, 2026 AGM as Late-Stage Angioedema Programs Advance - TipRanks
Pharvaris (Nasdaq: PHVS) details AGM plans and NDA timeline for HAE therapy - Stock Titan
Shareholders of Pharvaris to vote at June 26 annual meeting - Stock Titan
Why Pharvaris (PHVS) Is Up 8.6% After Expanding Deucrictibant HAE Data And Regulatory Plans - Sahm
Pharvaris N.V. (PHVS) Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Progress in HAE Pipeline - newsline.com
Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000 - AOL.com
Insider Sell: Anna Nijdam Sells Shares of Pharvaris NV (PHVS) - GuruFocus
Pharvaris (PHVS) accounting officer sells 2,670 common shares on market - Stock Titan
A Look At Pharvaris (PHVS) Valuation As Deucrictibant Data Advances Toward Key EAACI 2026 Catalyst - Sahm
Understanding Momentum Shifts in (PHVS) - Stock Traders Daily
Anna Nijdam reports sales of PHVS common shares (PHVS) - Stock Titan
PHVS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Pharvaris N.V. (PHVS) Presents at The 2026 Eastern Allergy ConferenceSlideshow (NASDAQ:PHVS) 2026-05-30 - Seeking Alpha
Pharvaris (PHVS) Holds Near Resistance as Shares Edge Higher on Modest VolumeRetail Driven Moves - The Legal Advocate
Pharvaris Trades Flat as Investors Wait for June Data Update - Bez Kabli
Pharvaris (PHVS) Edges Higher Amid Tight Trading Range, Testing Resistance at $31.61Death Cross - The Legal Advocate
Hereditary angioedema oral drug data headed to European allergy congress - Stock Titan
Pharvaris (PHVS) director Monges sells 9,667 shares, updates ownership - Stock Titan
Pharvaris (PHVS) accounting officer exercises options, sells 7,330 shares - Stock Titan
Pharvaris (PHVS) CFO/CLO Nassif sells 10,000 shares, corrects ownership - Stock Titan
Oppenheimer maintains Pharvaris NV (PHVS) outperform recommendation - MSN
Avoiding Lag: Real-Time Signals in (PHVS) Movement - Stock Traders Daily
B of A Securities Upgrades Pharvaris N.V. (PHVS) - MSN
Anna Nijdam proposes sale of 5,501 PHVS shares via Morgan Stanley (PHVS) - Stock Titan
Pharvaris (PHVS) director sells 10,000 shares, exercises options under 10b5-1 - Stock Titan
Pharvaris (PHVS) CEO Berndt Modig updates direct and indirect share holdings - Stock Titan
[144] Pharvaris N.V. SEC Filing - Stock Titan
Pharvaris (PHVS) CEO Modig sells 2,292 shares under Rule 10b5-1 plan - Stock Titan
PHVS (NASDAQ) Form 144/A: brokered resale of 4,667 and 5,333 common shares - Stock Titan
Director Robert Glassman of Pharvaris (PHVS) sells 10,000 shares after exercising options - Stock Titan
Pharvaris (PHVS) technical ops chief sells 8,748 shares in open market - Stock Titan
Pharvaris (PHVS) CCO Souverijns sells 10,000 shares under Rule 10b5-1 plan - Stock Titan
Pharvaris N.V. (PHVS) Fell -5.23% — Is a Recovery Ahead? 2026-05-18{涓偂鍓爣棰榼 - Newser
Pharvaris N.V. (PHVS) Delivers Q1 2026 Beat — EPS $-0.59 vs $-0.73 ExpectedShare Dilution Risk - Newser
The Bull Case For Pharvaris (PHVS) Could Change Following Major Equity Raise And NDA ProgressLearn Why - simplywall.st
Viking Global affiliates hold 3.65M shares of Pharvaris (PHVS) after amendment - Stock Titan
PHVS (NASDAQ: PHVS) reports 10b5-1 sales of 23,333; 2,292 RSUs - Stock Titan
Affiliate files notice to sell 4,667 & 4,137 shares (NASDAQ: PHVS) - Stock Titan
Pharvaris N.V. (PHVS) Q4 2025 Earnings Miss: EPS $-0.72 vs $-0.63 ExpectedEarnings Surprise Report - Newser
Discipline and Rules-Based Execution in PHVS Response - Stock Traders Daily
Why Pharvaris Shares Are Suddenly Sliding Today - TipRanks
Pharvaris Equity Raise Supports Late Stage HAE Push And Valuation Case - Yahoo Finance
Pharvaris (PHVS) CMO reports 226 shares withheld for RSU taxes - Stock Titan
Pharvaris N.V. Stock 12‑Month Price Target Cut to $46.57, Implies 49% Upside - TradingView
Pharvaris N.V. Stock 12‑Month Price Target Cut to $46.51, Implies 49% Upside - TradingView
Pharvaris Nv (PHVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Pharvaris Nv 주식 (PHVS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Nijdam Anna | Principal Accounting Officer |
Jun 04 '26 |
Sale |
30.87 |
2,670 |
82,425 |
46,275 |
2.60%
0.94%
자본화:
|
볼륨(24시간):